PBRM1 and Miyoshi myopathy: Recent evidence suggests that PBRM1 genomic alterations are strongly associated with neoantigen production and responsiveness to immune checkpoint inhibitors (ICIs), therefore, the analysis of the expression levels and gene mutation affecting this gene may be predictive for the therapeutic choice in MM.